Un nouveau rapport aidera la FDA à évaluer les futurs traitements de la dégénérescence frontotemporale

Today, AFTD released Frontotemporal Degeneration (FTD): A Voice of the Patient Report. This report will provide the FDA with data and insights to evaluate future studies and treatments for FTD, the most common form of dementia under 60. As one family member describes it, FTD is the “cruelest, most unrelenting disease… We need relief, and it cannot come soon enough.” Today, there is no cure, and there are no FDA-approved symptomatic or disease-modifying treatments.

Cliquez ici pour en savoir plus.

Rester informé

color-icon-laptop

Inscrivez-vous maintenant et restez au courant des dernières nouvelles avec notre newsletter, des alertes d'événements, et plus encore…